证券代码：688177 证券简称：百奥泰 公告编号：2025-036 百奥泰生物制药股份有限公司 第二届监事会第二十次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 监事会会议召开情况 百奥泰生物制药股份有限公司（以下简称"公司"）第二届监事会第二十次会 议（以下简称"本次会议"）于 2025 年 4 月 28 日在线上以通讯方式召开，本次会 议通知及相关材料已于 2025 年 4 月 17 日以书面方式送达公司全体监事。本次会 议由监事会主席吴晓云召集并主持，会议应出席监事 3 人，实际出席监事 3 人。 会议的召集、召开和表决程序符合《中华人民共和国公司法》《上海证券交易所 科创板股票上市规则》等相关法律、行政法规、规范性文件及《百奥泰生物制药 股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、 监事会会议审议情况 经与会监事充分讨论，本次会议以记名投票方式审议通过了如下议案： 审议通过《关于公司 2025 年第一季度报告的议案》 经审议，监事会认为公司 2025 年第一季度报告的 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 206,555,604.43, representing a 27.83% increase compared to CNY 161,591,937.51 in the same period last year[3] - The net profit attributable to shareholders was a loss of CNY 93,330,977.90, an improvement from a loss of CNY 118,958,055.48 year-over-year[3] - The net loss for Q1 2025 was ¥93,330,977.90, an improvement from a net loss of ¥118,958,055.48 in Q1 2024[20] - The company reported a total comprehensive loss of -93,667,998.14 RMB for Q1 2025, compared to -119,035,070.61 RMB in Q1 2024, showing a reduction in losses[35] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 79,416,905.66, a significant recovery from a negative cash flow of CNY 64,803,155.03 in the previous year[3] - Operating cash flow for Q1 2025 was ¥79,416,905.66, a significant improvement from -¥64,803,155.03 in Q1 2024[25] - Cash inflow from operating activities in Q1 2025 was 389,351,258.04 RMB, compared to 220,047,817.51 RMB in Q1 2024, reflecting a growth of about 77%[37] - The total cash and cash equivalents at the end of Q1 2025 reached 472,171,686.61 RMB, up from 292,801,722.94 RMB at the end of Q1 2024, representing an increase of approximately 61.4%[38] Research and Development - R&D expenses totaled CNY 180,224,489.76, which is a 5.01% increase from CNY 171,622,215.16, accounting for 87.25% of revenue, down from 106.21%[3] - R&D expenses increased to ¥180,224,489.76 in Q1 2025, compared to ¥171,622,215.16 in Q1 2024, marking a growth of 5.8%[19] - The company continues to focus on R&D and market expansion strategies to improve future performance[19] Assets and Liabilities - Total assets increased by 6.35% to CNY 2,345,641,403.78 from CNY 2,205,537,745.47 at the end of the previous year[4] - Total assets increased to ¥2,345,641,403.78 in Q1 2025 from ¥2,205,537,745.47 in Q1 2024, representing a growth of 6.4%[17] - Total liabilities rose to ¥1,730,911,199.49 in Q1 2025, up from ¥1,497,448,743.34 in Q1 2024, indicating an increase of 15.6%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,526[9] - Guangzhou Qixi Group Co., Ltd. holds 38.64% of the shares, making it the largest shareholder[10] - Therabio International Limited is the second largest shareholder with 11.39% of the shares[10] Government Support - The company received government subsidies amounting to CNY 6,233,653.05, which positively impacted the financial results[5] Other Financial Metrics - The weighted average return on equity was -14.11%, a decrease of 3.79 percentage points from -10.32% in the previous year[3] - Basic and diluted earnings per share for Q1 2025 were both -¥0.23, compared to -¥0.29 in Q1 2024[21] - The company reported a net profit margin improvement with a net income of ¥6,228,094.38 in Q1 2025, compared to ¥2,518,299.72 in Q1 2024[33]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

中国经济网北京4月24日讯 百奥泰(688177.SH)昨晚发布股东减持股份计划公告。 截至公告披露日，新余市启恒管理咨询合伙企业(有限合伙)(曾用名："东台市启恒医药合伙企业(有 限合伙)""珠海吉富启恒医药投资合伙企业(有限合伙)"，以下简称"新余启恒")及其一致行动人汇天泽投资 有限公司(以下简称"汇天泽")合计持有百奥泰生物制药股份有限公司(以下简称"公司")20,704,000股，占 公司总股本5.00%，其中流通股股份数量为20,704,000股，占公司总股本5.00%。 | 股东名称 | 新余启恒 | | --- | --- | | 计划减持数量 | 不超过:8,281,600 股 | | 计划减持比例 | 不超过:2.00% | | 减持方式及对应减持数量 | 集中竞价减持,不超过:4,140,800 股 | | | 大宗交易减持,不超过:4,140,800 股 | | 减持期间 | 2025年5月20日~2025年8月19日 | | 拟减持股份来源 | IPO 前取得 | | 拟减持原因 | 项目退出及资金安排 | 百奥泰于2020年2月21日在上交所科创板上市，发行价格为32.76元/股， ...

Group 1 - Shareholders of Tietuo Machinery plan to reduce their holdings by up to 1,800,000 shares, representing 1.95% of the total share capital, within 15 trading days until August 1, 2025 [1] - Senior management of Upower Electric completed their share reduction plan, with one executive reducing 1,605,000 shares, accounting for 0.0448% of the total share capital after excluding repurchased shares [2] - Jiangsu Jianghai Machinery, a major shareholder of Zhonghuan Hailu, has completed its share reduction plan, reducing 975,908 shares, which is 0.9759% of the total share capital [3] Group 2 - Major shareholders of Duopule plan to reduce their holdings by up to 3,000,000 shares, or 4.85% of the total share capital, within three months after 15 trading days [4] - Shareholders of Jinpu Garden plan to reduce their holdings by up to 1,839,313 shares, each accounting for 1% of the total share capital, within three months [5] - Major shareholders of Liaoning Energy plan to reduce their holdings by up to 39,660,520 shares, representing 3% of the total share capital, within three months after 15 trading days [6] Group 3 - Senior management of Qianzhao Optoelectronics has terminated their share reduction plan without executing any share sales [7] - Major shareholders of Wolong Nuclear Materials plan to reduce their holdings by up to 24,926,600 shares, or 2% of the total share capital, within three months after 15 trading days [8] - Major shareholders of Taiyong Changzheng plan to reduce their holdings by up to 6,695,765 shares, representing 3% of the total share capital, within three months after 15 trading days [9] Group 4 - Major shareholders of Dagang Holdings plan to reduce their holdings by up to 9,520,000 shares, approximately 3% of the total share capital, within three months after 15 trading days [10] - Directors of Yawey Holdings plan to reduce their holdings by up to 4,716,250 shares, or 0.86% of the total share capital, within three months after 15 trading days [11] - Shareholders of Source Fly Pet plan to reduce their holdings by up to 5,651,413 shares, representing 3% of the total share capital, within three months after 15 trading days [12] Group 5 - Major shareholders of Jiangsu Boyun plan to reduce their holdings by up to 2,913,999 shares, or 3% of the total share capital, within three months after 15 trading days [13] - Directors of Supor plan to reduce their holdings by a total of 99,080 shares within three months after 15 trading days [14] - Major shareholders of Yinglian Holdings plan to reduce their holdings by up to 10,458,200 shares, each accounting for 2.50% of the total share capital, within three months after 15 trading days [15]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688177 证券简称：百奥泰 公告编号：2025-035 百奥泰生物制药股份有限公司 关于召开2024年度科创板集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议召开时间：2025年5月8日（星期四） 15:00-17:00 ● 投资者可于2025年4月28日（星期一）至5月7日（星期三）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱IR@bio-thera.com进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 百奥泰生物制药股份有限公司（以下简称"公司"）已于2025年4月9日发布公司2024年年度报告，为便于 广大投资者更全面深入地了解公司2024年度经营成果、财务状况，公司计划于2025年5月8日（星期四） 15:00-17:00举行2024年度科创板集体业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动形式召开，公司将针对202 ...

百奥泰生物制药股份有限公司 关于召开 2024 年度科创板集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688177 证券简称：百奥泰 公告编号：2025-035 重要内容提示： 会议召开时间：2025 年 5 月 8 日（星期四） 15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 28 日（星期一）至 5 月 7 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bio-thera.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 百奥泰生物制药股份有限公司（以下简称"公司"）已于 2025 年 4 月 9 日发 布公司 2024 年年度报告，为便于广大投资者更全面深入地了解公司 2024 年度经 营成果、财务状况，公司计划于 ...

证券代码：688177 证券简称：百奥泰 公告编号：2025-034 百奥泰生物制药股份有限公司 股东持有的基本情况 截至本公告披露日，新余市启恒管理咨询合伙企业（有限合伙）（曾用名："东 台市启恒医药合伙企业（有限合伙）""珠海吉富启恒医药投资合伙企业（有限合 伙）"，以下简称"新余启恒"）及其一致行动人汇天泽投资有限公司（以下简称"汇 天泽"）合计持有百奥泰生物制药股份有限公司（以下简称"公司"）20,704,000 股，占公司总股本 5.00%，其中流通股股份数量为 20,704,000 股，占公司总股本 5.00%。 减持计划的主要内容 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 新余启恒因投资项目退出及资金安排需要计划通过集中竞价、大宗交易方式 减持其持有的公司股份，合计不超过 8,281,600 股（含本数），占公司总股本不超 过 2%。其中，通过集中竞价交易方式减持股份不超过 4,140,800 股（含本数）， 占公司总股本不超过 1%；通过大宗交易方式减 ...

�����������������������������������������������������������������������������������������������2%� ...

Core Viewpoint - Baiotai Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of BAT7111, a drug intended for the treatment of advanced solid tumors [2][3] Group 1: Clinical Trial Approval - The drug BAT7111 is a PD-1/4-1BB bispecific antibody developed by the company, aimed at treating advanced solid tumors [3] - The clinical trial application for BAT7111 was accepted on February 12, 2025, and has been approved to proceed with clinical trials [2][3] Group 2: Drug Composition and Mechanism - BAT7111 consists of a recombinant humanized anti-PD-1 antibody and a fully human 4-1BB single-domain antibody, which can block the PD-1/PD-L1 immune suppression pathway and activate immune cells [3] - The design of differential affinity for PD-1 antibodies and 4-1BB antibodies aims to enhance safety and potentially improve the efficacy of existing PD-1 therapies [3] Group 3: Clinical Development Insights - According to data from "Clinical Development Success Rates 2011-2020," the typical duration for Phase I/II clinical trials for anti-tumor drugs is about 2 years, with a 48.8% transition rate from Phase I to II and a 24.6% transition rate from Phase II to III [2][5] - The company will analyze trial data to determine the safety and efficacy of the drug, which will inform the progression of subsequent clinical trials [5]